10/19/2005 5:12:44 PM
COLUMBIA, Md.--(BUSINESS WIRE)--Feb. 15, 2005--Hemagen Diagnostics, Inc. (OTCBB:HMGN.OB) a biotechnology company that develops, manufactures, and markets proprietary medical diagnostic test kits, today reported operating results for the first fiscal quarter ended December 31, 2004. For the three-month period ended December 31, 2004, the net loss was $235,000 or $(0.02) per share, compared to a net loss of $574,000 or ($0.06) per share for the period ended December 31, 2003. After adjusting for non-cash charges including depreciation, amortization, and non-cash interest, the net loss for the quarter ended December 31, 2004 was $103,000 compared to a net loss of $68,000 for the quarter ended December 31, 2003.
comments powered by